Destiny Pharma Scientific Advisor, Professor Dale Gerding, to chair C. diff. Foundation Symposium

Brighton, United Kingdom – 02 July 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines to prevent life-threatening infections, is pleased to announce that its Scientific Advisory Board member, Professor Dale Gerding, a world-leading expert in C. difficile infections (CDI) and the discoverer of NTCD-M3, will be chairing the “C. diff. Patient, Family, and Caregiver” Symposium, to be held virtually on 16 July 2021.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH